Our goal is to deliver novel and differentiated oral small-molecule therapies to patients living with diseases with significant unmet medical need.

We are currently in Phase 3 clinical development evaluating our product candidate, lanifibranor, for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as NASH. Lanifibranor is an orally available small molecule designed to address the key drivers of MASH by inducing anti-fibrotic, anti-inflammatory and beneficial metabolic changes through the activation of all three peroxisome proliferator-activated receptor, or PPAR, isoforms.